UCB, Nodality sign multi-year research collaboration
UCB Pharma and Nodality have entered into a multi-year strategic collaboration utilizing Nodality's single cell network profiling (SCNP) technology to assist the development of several UCB compounds.
The agreement will initially focus on immunology disorders. It also gives UCB the option to engage Nodality to develop companion diagnostics for UCB's compounds.
The terms of the agreement include an upfront payment, R&D funding, and success-based milestones if all applicable development, regulatory and commercialization milestones are achieved.
In addition, Nodality may be eligible for royalties on future diagnostic sales.
The details of the terms have not been disclosed.
Nodality CEO David Parkinson said based on their application of SCNP platform to malignant and autoimmune diseases, they will be able to add significant value to UCB's drug development portfolio.
Related Insight
Suppliers Directory
Trigona – Synthesis Development and Kilogram Synthesis
Trigona oHG, a privately-held chemical company, is engaged in the synthesis, development and multi-kilogram manufacturing of chemical products.
Contract Research & Services > Contract Research > Suppliers
World Courier - Offering Fully-Integrated GxP-Compliant Global Transport and Storage for the Pharmaceutical Industry
For over 40 years, World Courier has set the standard for worldwide time- and temperature-sensitive transportation services to the pharmaceutical industry. World Courier works with customers to ensure regulatory compliance and supply chain integrity, and to identify and deliver the best logistical solutions for each individual study or consignment.
Contract Research & Services > Contract Research > Suppliers
NEUROFIT - Preclinical Research
NEUROFIT is a CRO (Contract Research Organisation) specialised in the evaluation of treatments for central (CNS) and peripheral nervous system (PNS) disorders, autoimmune diseases and for Oncology.
Contract Research & Services > Contract Research > Suppliers
FOCUS Clinical Drug Development - Exploratory Drug Development of NCEs / NBEs
FOCUS Clinical Drug Development is an independent full-service CRO specialised in early clinical development and integrated proof of concept (PoC) packages. FOCUS has conducted more than 600 high-quality early-phase clinical studies in healthy volunteers and many patient populations.
Contract Research & Services > Contract Research > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Contract Research Intelligence
Contamination Problems? We Solve Them
Published by Phage Consultants
Contract Research & Services > Contract Research > White Papers
Clinical Pharmacodynamics Services
Published by FOCUS Clinical Drug Development
Contract Research & Services > Contract Research > White Papers
Heating Has Never Been So Cool
Published by SCA Cool Logistics
Contract Research & Services > Contract Research > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.